1. Introduction {#sec1-jcm-09-00660}
===============

Diabetes mellitus is one of the major global health problems in an aging society. Driven by aging and aging-related comorbidities, diabetes mellitus continues to increase in prevalence, not only in Taiwan, but also around the world. In Taiwan, the prevalence of type 2 diabetes (T2D) was reported by community studies to be up to 26.9% among those aged over 65 years \[[@B1-jcm-09-00660]\]. In addition, the prevalence of dementia accounted for 2% to 5% of the population aged over 65 years \[[@B2-jcm-09-00660]\], and this has placed a heavy burden on dementia patients, their caregivers and the community \[[@B3-jcm-09-00660],[@B4-jcm-09-00660],[@B5-jcm-09-00660]\].

Alzheimer's disease (AD) and vascular dementia are the most common types of dementia and share both vascular and neurodegenerative pathophysiological mechanisms \[[@B6-jcm-09-00660],[@B7-jcm-09-00660]\]. Excluding the vascular mechanism, the other postulated mechanisms for the association between AD and T2D include hyperglycemia, inflammation, brain insulin resistance, the reduced degradation of β-amyloid peptides secondary to the formation of advanced glycation end products, and competition for the insulin-degrading enzyme; in fact, AD is being considered as type 3 diabetes \[[@B8-jcm-09-00660],[@B9-jcm-09-00660]\]. A previous study disclosed that diabetes mellitus was associated with a 1.7-fold greater risk of dementia among elderly people \[[@B10-jcm-09-00660]\]. Furthermore, T2D was a significant risk factor for not only AD, but also for vascular dementia \[[@B11-jcm-09-00660]\].

In both nondiabetic and T2D subjects, there are several risk factors for dementia development \[[@B12-jcm-09-00660]\]. T2D-related therapy and its comorbidities were associated with an increasing incidence of dementia \[[@B13-jcm-09-00660]\]. There were a few studies that explored the risk factors and/or validated a practical risk score to predict the future risk of dementia among individuals with T2D \[[@B14-jcm-09-00660]\]. Among these risk factors, antidiabetic medications were extensively evaluated for their potential risks and benefits. However, the results remained controversial for old antidiabetic medications. For example, there were studies that demonstrated a diminished risk of dementia with metformin use \[[@B15-jcm-09-00660]\], but these benefits were found in the age group of \<75 years and in patients on high-dose metformin \[[@B16-jcm-09-00660],[@B17-jcm-09-00660]\]. These results for other antidiabetic medications were also inconclusive, including for sulfonylureas and thiazolidinediones \[[@B8-jcm-09-00660],[@B18-jcm-09-00660],[@B19-jcm-09-00660]\].

On the other hand, studies that have explored the role of dipeptidyl peptidase 4 inhibitors (DPP-4i) on dementia development in patients with T2D have been limited. A previous animal study reported that DPP-4i improved the functions of the neuronal insulin receptor and the brain mitochondria, and that it can delay some forms of AD-like pathology \[[@B20-jcm-09-00660]\]. In addition, sitagliptin was reported to have a possible association with the improvement of cognitive function in elderly diabetic patients with and without AD \[[@B21-jcm-09-00660]\]. However, a recent study revealed that therapy with linagliptin did not improve the cognitive performance of patients with T2D and cardiorenal disease \[[@B22-jcm-09-00660]\]. According to present evidence, the effects of DPP-4i on dementia remain inconclusive. In addition, it remains to be clarified whether the association of DPP-4i with dementia is a class effect or is affected by other factors, such as treatment duration.

Therefore, we carried out a study to investigate the association between DPP-4i use and the different types of dementia, as well as the impact of the different types and therapeutic durations of DPP-4i among patients with diabetes. We assessed the incidence of dementia in diabetic patients aged ≥50 years and on DPP-4i use, on the basis of the National Health Insurance Research Database (NHIRD), which was a claims database that was retrieved from the entire population of Taiwan.

2. Materials and Methods {#sec2-jcm-09-00660}
========================

2.1. Data Sources {#sec2dot1-jcm-09-00660}
-----------------

In this study, we used 7 year data from the NHIRD, based on the two million included in the Longitudinal Health Insurance Database (LHID) in Taiwan (2008 to 2015). The National Health Insurance (NHI) Program was launched in Taiwan in 1995, and as of June 2009, included contracts with 97% of the medical providers, with approximately 23 million beneficiaries, or more than 99% of the entire population \[[@B23-jcm-09-00660]\]. The NHIRD uses the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to record the diagnoses. All diagnoses of T2D were made by board-certified internists, endocrinologists, or other related specialists, and all diagnoses of dementia were made by board-certified psychiatrists or neurologists. The NHI administration randomly reviews the records of ambulatory care visits and inpatient claims periodically to verify the accuracy of the diagnoses. The NHIRD was therefore considered appropriate for this study on the association between dementia and use of DPP-4i.

2.2. Study Design and Sampled Participants {#sec2dot2-jcm-09-00660}
------------------------------------------

Sitagliptin was the first DDP-4i approved by the United States Food and Drug Administration on October 16, 2006, and has been marketed in Taiwan since 2008. This study was a retrospective matched-cohort design between January 1, 2008 and December 31, 2015. From the LHID, we identified and selected 5028 patients with diabetes (ICD-9-CM 250.XX) and who used DPP-4i for \>90 days. Each enrolled patient was required to have made at least three outpatient visits within the study period. The diabetic patients who were \<50 years old, those previously diagnosed with dementia, and those who were on DPP-4i before the index date were excluded. In addition, patients who received GLP-1 agonist before the tracking were excluded.

Data on the use of DPP-4i, including sitagliptin, linagliptin, saxagliptin, vildagliptin, and alogliptin, were collected. This study enrolled 2903 patients on DPP-4i use (DPP-4i group), and 11,612 patients without DPP-4i use (non-DPP-4i group) were matched by 1:4 propensity score matching, using confounding variables including sex, age, comorbidities, medication and index year. ([Figure 1](#jcm-09-00660-f001){ref-type="fig"}).

2.3. Comorbidity {#sec2dot3-jcm-09-00660}
----------------

The comorbidities included hypertension, hyperlipidemia, obesity, microvascular or macrovascular complications of diabetes, heart failure, depression, hearing loss, and atrial fibrillation. The microvascular complications included retinopathy, nephropathy, and neuropathy, whereas the macrovascular complications included stroke, coronary artery disease, and peripheral atrial occlusive disease. In addition, the Charlson comorbidity index was used to categorize the comorbidities based on the ICD-9-CM codes; the scores for each comorbidity category were combined into a single comorbidity score. A score of zero indicated that no comorbidities were found, and higher scores indicated a higher comorbidity burden \[[@B24-jcm-09-00660]\].

2.4. Outcome Measurements {#sec2dot4-jcm-09-00660}
-------------------------

All study participants were followed up from the index date until the diagnosis of dementia (ICD 9-CM codes: 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.41, 290.42, 290.43, 290.8, 290.9, and 331.0), withdrawal from the NHI program, or at the end of 2015. These patients with dementia were grouped as AD (ICD-9-CM331.0), vascular dementia (ICD-9-CM 290.41--290.43), and other dementia (ICD-9-CM 290.0, 290.10--290.13, 290.20--290.21, 290.3, 290.8--290.9).

2.5. Statistical Analysis {#sec2dot5-jcm-09-00660}
-------------------------

All analyses were performed using the SPSS software version 22 (SPSS Inc., Chicago, IL, USA). The χ^2^ test and Student's t-test were used to evaluate the distribution of the categorical and continuous variables, respectively. The Fisher's exact test was used to analyze the differences in categorical variables between the two cohorts. Multivariate Cox proportional hazards regression analysis was used to determine the risk of dementia, and the results were presented as hazard ratios (HR) with 95% confidence intervals (CI). The difference in the risk of dementia between the DPP-4i and the non-DPP-4i groups was estimated using the Kaplan--Meier method with the log-rank test. A two-tailed *p* value of \<0.05 was considered to indicate statistical significance.

2.6. Ethics Approval {#sec2dot6-jcm-09-00660}
--------------------

This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The institutional review board of the Tri-Service General Hospital approved this study (IRB No. 2-107-05-026 and IRB No. 1-106-05-169).

3. Results {#sec3-jcm-09-00660}
==========

[Table 1](#jcm-09-00660-t001){ref-type="table"} demonstrates the demographics of the study population. There were 2903 patients in the DPP-4i group and 63,430 patients in the non-DPP-4i group. After propensity score matching at a ratio of 1:4, 11,612 pairs remained. Both groups had a mean age of 68 years, had female preponderance (61.8%), and were followed up for a mean duration of 7 years. Of the 14,515 enrollees, dementia developed in 191 (6.5%) of the study subjects and in 913 (7.8%) of the matched controls. [Figure 2](#jcm-09-00660-f002){ref-type="fig"} demonstrates that the cumulative incidence of dementia was lower in the DPP-4i group than in the non-DPP-4i group (*p* \< 0.001).

[Table 2](#jcm-09-00660-t002){ref-type="table"} shows the Cox regression analysis of the association between DPP-4i use and the risk of developing different kinds of dementia. The crude HR of overall dementia was 0.772 (95% CI 0.663--0.856; *p* \< 0.001) and remained significant after adjusting for confounding variables (adjusted HR 0.798; 95% CI 0.681--0.883; *p* \< 0.001). Compared with the non-DPP4i group, the DPP-4i group had associated decreased risks for developing vascular dementia (adjusted HR 0.575; 95% CI 0.404--0.681; *p* \< 0.001) and the other types of dementia (adjusted HR 0.684; 95% CI 0.556--0.749; *p* \< 0.001), but not AD (adjusted HR 0.891; 95% CI 0.712--1.265; *p* = 0.297). The results were the same, even after the exclusion of individuals who were diagnosed as having dementia within the first year and the first 5 years. The reduction in the risk of dementia development in the DPP-4i group was independent of age, sex, and the presence of microvascular and macrovascular complications ([Table 3](#jcm-09-00660-t003){ref-type="table"}).

[Table 4](#jcm-09-00660-t004){ref-type="table"} shows the comparison of the risk of dementia among the different types of DPP-4i. All types of DPP-4i had significant protective effects against dementia development. Moreover, there was a cumulative protective effect of all of the types of DPP-4i, especially when the duration of therapy was greater than 1 year. The associated decreased risk of dementia with DPP-4i use for less than 1 year was observed only in patients treated with sitagliptin or saxagliptin.

4. Discussion {#sec4-jcm-09-00660}
=============

Our study demonstrated that compared with non-DPP-4i use, DPP-4i use was associated with a 21% lower risk of developing all types of dementia in older patients with T2D. Furthermore, the DPP-4i types seemed to have a class effect that was dose-dependent. This information may be important for physicians when choosing the optimal antidiabetic medications for patients of T2D with or without dementia.

DPP-4 inhibitor, which is one of the incretin-based therapies that increase the concentration of circulating GLP-1, has been frequently used for the treatment of T2D because of its relatively low risk of inducing hypoglycemia \[[@B25-jcm-09-00660]\]. Our results demonstrated that the types of DPP-4i had a class effect on dementia prevention, with a main focus on vascular dementia, but not on AD. These results were not consistent with those of previous human studies \[[@B21-jcm-09-00660],[@B22-jcm-09-00660],[@B26-jcm-09-00660]\]. The discrepancy among the studies may be attributed to the populations and numbers of the study participants, study designs, durations of follow up, and end points of the studies (cognition and dementia definitions and types). The CARMELINA-COG study is the only randomized controlled trial to evaluate the effect of using DPP-4i on cognition function, and the results showed that linagliptin therapy did not modulate cognitive decline in patients with T2D and cardiorenal comorbidities. This study used the Mini-Mental State Examination (MMSE) to evaluate cognitive function, instead of the risk of dementia development, with a mean 2.5 year follow-up \[[@B22-jcm-09-00660]\]. Similarly, Isik et al. demonstrated that sitagliptin therapy improved the cognitive function of elderly patients with T2D, regardless of a prior history of AD. However, the duration of follow up was only 6 months \[[@B21-jcm-09-00660]\]. The latest nested case control study from a cohort of 176,250 patients registered in the Danish National Diabetes Register study showed that the use of DPP-4i in T2D patients significantly decreased the risk of dementia compared to in non-DPP-4i users during a long duration of follow up (7.2 years). However, this study did not reveal the effect of DPP-4i on different types of dementia \[[@B26-jcm-09-00660]\].

GLP 1 receptors are expressed in the neurons of the central nervous system. Stimulation of the GLP-1 receptor could attenuate neuroinflammation and enhance neurogenesis in diabetes-induced dementia, in animal models \[[@B27-jcm-09-00660],[@B28-jcm-09-00660]\]. The concept was supported by a small randomized, controlled study in humans, which showed that liraglutide therapy improved memory function in obese patients with prediabetes or early type 2 diabetes, independently of weight loss and the glycemic lowering effect \[[@B29-jcm-09-00660]\]. Therefore, increased circulating GLP 1 concentrations from DPP-4i therapy may have a neuroprotective role in the treatment of dementia. According to previous animal experimental studies, the neuroprotective effects of DPP-4i were evident in improving learning behavior and memory in AD and/or vascular dementia among the different types of DPP-4i \[[@B30-jcm-09-00660],[@B31-jcm-09-00660],[@B32-jcm-09-00660],[@B33-jcm-09-00660],[@B34-jcm-09-00660],[@B35-jcm-09-00660],[@B36-jcm-09-00660]\]. The mechanisms of DPP-4i on vascular dementia found in animal studies included attenuating endothelial dysfunction, reducing cerebral oxidative stress, and decreasing ischemic brain damage, via a glucose-independent mechanism, likely involving GLP-1 \[[@B30-jcm-09-00660],[@B33-jcm-09-00660],[@B34-jcm-09-00660]\]. Moreover, the complex pathophysiology of AD, which involves vascular and non-vascular mechanisms, is documented and characterized by the accumulation of aggregated amyloid-β (Aβ) protein and hyper-phosphorylated tau protein, neuroinflammation, and a reduction in cerebral glucose consumption \[[@B37-jcm-09-00660]\]. DPP4 might play (a) role(s) in amyloid formation according to an in vitro experiment, and DPP-4i decreased amyloid-β deposition and tau phosphorylation by increasing hippocampal GLP-1 levels \[[@B36-jcm-09-00660]\]. These results implied the beneficial effects of DPP-4i therapy on AD development. Furthermore, not all of the previous animal studies showed neuroprotection with DPP-4i. A previous animal study showed that sitagliptin may increase the risk of dementia by aggravating tau phosphorylation and insulin resistance in the brain \[[@B38-jcm-09-00660]\]. Therefore, the complex pathophysiological mechanism involved in AD development may partly account for the absence of a diminished risk of AD from DPP 4i therapy in the current study.

Thus, although it is generally considered that the use of DPP 4i has a beneficial impact on cognition function, it still remains inconclusive that there is a beneficial effect of DPP 4i therapy on diminishing the risk of different types of dementia development, according to the current experimental and clinical studies. A further, large-scaled, RCT trial should be designed to clarify this issue.

Hypoglycemia is considered to be an independent risk factor for dementia development \[[@B39-jcm-09-00660]\]; the risk of dementia in DPP-4i users should be lower than in users of other, older oral antidiabetic agents. A Korean cohort study showed that compared with sulfonylurea, DPP-4i decreased the risk of dementia in elderly patients with T2D. However, contrary to this present study, that study showed benefits in AD but not in vascular dementia \[[@B40-jcm-09-00660]\]. The results are similar to those from another retrospective longitudinal study of metformin-based therapy, in which adding DPP-4i was shown to better protect against worsening cognitive function than sulfonylureas, in older patients with T2D and mild cognitive impairment \[[@B41-jcm-09-00660]\]. Sulfonylureas have been associated with the risk of hypoglycemia, which had been commonly overused in older patients \[[@B42-jcm-09-00660]\]. In addition, glycemic fluctuations might contribute to poor cognitive outcomes \[[@B43-jcm-09-00660]\]. On the other hand, compared with other oral antidiabetic agents, especially sulfonylureas, DPP-4i provides steady glucose variability \[[@B44-jcm-09-00660],[@B45-jcm-09-00660]\]. Accordingly, our study results demonstrate the independent benefits of DPP-4i use in preserving the cognitive function of patients with diabetes.

In our subgroup analysis, the association between DPP-4i use and the decreased risk of dementia was evident in patients aged ≥50 years, regardless of the presence of diabetes complications. Nevertheless, we found that the benefits of DPP-4i were weaker in those ≥65 years old and in those with macrovascular or microvascular complications of diabetes. The results were similar to those in a recent study that showed that overall, linagliptin did not reduce cognitive decline in patients with T2D and cardiorenal comorbidity \[[@B22-jcm-09-00660]\]. Therefore, the protective effect of DPP-4i against dementia may be greater in younger patients and those without diabetic complications.

There were several limitations of this study. Although these insurance claims data allowed the identification of patients with dementia or diabetes, data on diabetes severity, duration, and impact of control, such as glycated hemoglobin levels, were not available. Owing to the retrospective design, patients with mild cognitive decline may have been underdiagnosed. Other residual confounding factors, such as education, genetics or dietary factors, and body mass index, were not included in the NHIRD. In addition, because this was a population-based study, the actual mechanism for the association between DPP-4i use and dementia in patients with T2D cannot be clarified.

In conclusion, compared with non-DPP-4i use, DPP-4i use was associated with a lower risk of dementia in older Taiwanese patients with T2D. Further study on the neuroprotective effects of DPP-4i, based on a longer follow-up period, may be necessary to validate the risk of dementia with DPP-4i use.
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jcm-09-00660-t001_Table 1

###### 

Baseline characteristics of the matched pairs.

                                      With DPP-4i use   Without DPP-4i use   *p*
  ----------------------------------- ----------------- -------------------- -------
  N                                   2,903             11,612               
  Number of men (percentage)          1,109 (38.20%)    4,436 (38.20%)       0.999
  Age (years)                         68.05 ± 8.75      68.01 ± 8.69         0.808
  Age group (years)                                                          0.999
  50--64                              1,247 (42.96%)    4,988 (42.96%)       
  ≥65                                 1,656 (57.04%)    6,624 (57.04%)       
  Hypertension                        28.28             28.12                0.861
  Hyperlipidemia                      11.85             12.03                0.789
  Obesity                             0.07              0.07                 0.999
  Macrovascular complications of DM   20.43             20.76                0.690
  Microvascular complications of DM   22.94             22.50                0.613
  Heart failure                       2.00              2.02                 0.953
  Chronic kidney disease              17.43             17.28                0.852
  Depression                          4.06              3.91                 0.701
  Hearing loss                        4.10              3.95                 0.718
  Atrial fibrillation                 1.24              1.63                 0.131
  Obstructive sleep apnea             4.27              4.31                 0.919
  CCI_R                               1.24 ± 1.74       1.26 ± 1.80          0.558
  Medication used                                                            
  Metformin                           98.00             98.16                0.582
  Sulfonylureas                       89.46             88.52                0.153
  Glinide                             78.50             77.39                0.199
  Thiazolidinedione                   54.53             53.21                0.203
  AGi                                 19.70             19.98                0.740
  SGLT-2i                             18.98             18.32                0.410
  Insulin                             73.03             73.17                0.881

Categorical variables were compared using Chi-square or Fisher's exact test. Continuous variables were compared using Student's t-test. DM = diabetes mellitus; CCI_R = Charlson comorbidity index without dementia; DPP-4i = dipeptidyl peptidase 4 inhibitor; AGi=α-glucosidase inhibitor; SGLT-2i=Sodium--glucose co-transporter 2 inhibitor.

jcm-09-00660-t002_Table 2

###### 

The risk for dementia according to the use of DPP-4i.

                         All Dementia Cases     Dementia in the First Year Excluded   Dementia in the First 5 Years Excluded                                    
  ---------------------- ---------------------- ------------------------------------- ---------------------------------------- --------- ---------------------- ---------
  **Overall dementia**   0.798 (0.681--0.883)   \<0.001                               0.811 (0.682--0.901)                     \<0.001   0.849 (0.700--0.927)   0.005
  Alzheimer's disease    0.891 (0.712--1.265)   0.297                                 0.986 (0.789--1.303)                     0.297     1.265 (0.886--1.986)   0.596
  Vascular dementia      0.575 (0.404--0.681)   \<0.001                               0.612 (0.423--0.705)                     \<0.001   0.631 (0.497--0.786)   \<0.001
  Other dementia         0.684 (0.556--0.749)   \<0.001                               0.756 (0.589--0.834)                     \<0.001   0.793 (0.643--0.912)   0.001

HR was adjusted according to the variables listed in the baseline. DPP-4i = dipeptidyl peptidase 4 inhibitor; HR = hazard ratio, CI = confidence interval.

jcm-09-00660-t003_Table 3

###### 

Subgroup analyses on the use of DPP-4i according to sex, age, and microvascular and macrovascular complications of DM.

  DPP-4i                                  With   Without   With *vs.* without                                  
  --------------------------------------- ------ --------- -------------------- ------- ---------------------- ---------
  **Total**                               191    10.42     913                  13.74   0.798 (0.681--0.883)   \<0.001
  **Sex**                                                                                                      
  Male                                    66     10.14     326                  14.11   0.756 (0.643--0.836)   \<0.001
  Female                                  125    10.58     587                  13.54   0.822 (0.701--0.909)   \<0.001
  **Age group (years)**                                                                                        
  50--64                                  18     8.71      96                   12.38   0.742 (0.601--0.801)   \<0.001
  ≥65                                     173    10.64     817                  13.92   0.895 (0.727--0.976)   0.026
  **Macrovascular complications of DM**                                                                        
  Without                                 124    9.43      575                  12.36   0.713 (0.512--0.808)   \<0.001
  With                                    67     12.97     338                  16.97   0.804 (0.695--0.937)   0.005
  **Microvascular complications of DM**                                                                        
  Without                                 176    12.72     861                  16.13   0.706 (0.511--0.806)   \<0.001
  With                                    15     3.34      52                   3.98    0.835 (0.718--0.962)   0.013

The rate was calculated per 1000 person-years. HR was adjusted according to the variables listed in the baseline characteristics DM = diabetes mellitus; DPP-4i = dipeptidyl peptidase 4 inhibitor; HR = hazard ratio; CI = confidence interval.

jcm-09-00660-t004_Table 4

###### 

Comparison of the risk for dementia according to the use of DDP-4i.

                                 Adjusted HR   Lower CI   Higher CI   *p*
  ------------------------------ ------------- ---------- ----------- ---------
  **All DDP4i**                  0.798         0.681      0.883       \<0.001
  **All DDP4i (90--364 days)**   0.874         0.746      0.967       0.027
   Sitagliptin                   0.749         0.672      0.928       0.013
   Linagliptin                   0.861         0.768      1.002       0.051
   Saxagliptin                   0.769         0.683      0.927       0.009
   Vildagliptin                  0.901         0.801      1.397       0.244
   Alogliptin                    0.984         0.870      1.495       0.395
  **All DDP4i (≧365 days)**      0.780         0.665      0.864       \<0.001
   Sitagliptin                   0.669         0.599      0.788       \<0.001
   Linagliptin                   0.772         0.685      0.894       \<0.001
   Saxagliptin                   0.687         0.610      0.828       \<0.001
   Vildagliptin                  0.805         0.712      0.915       0.006
   Alogliptin                    0.879         0.778      0.971       0.031

HR was adjusted according to the variables listed in the baseline characteristics. DDP-4i = dipeptidyl peptidase 4; HR = hazard ratio; CI = 95% confidence interval.

[^1]: Equal contribution.
